Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Insights, Forecast to 2025

Publisher Name :
Date: 10-Jan-2019
No. of pages: 110
Inquire Before Buying

PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.

The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on company, product type, end user and key regions.

This report studies the global market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor in these regions.

This research report categorizes the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market by top players/brands, region, type and end user. This report also studies the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

- Tesaro

- Clovis Oncology

- AstraZeneca

- Abbvie

Market size by Product

- Lynparza

- Diraparib

- Rucaparib

- Talazoparib

- Others

Market size by End User

- Hospitals

- Pharmacial

- Retail

- Online

Market size by Region

- North America

- - United States

- - Canada

- - Mexico

- Asia-Pacific

- - China

- - India

- - Japan

- - South Korea

- - Australia

- - Indonesia

- - Singapore

- - Malaysia

- - Philippines

- - Thailand

- - Vietnam

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Spain

- - Russia

- Central & South America

- - Brazil

- - Rest of Central & South America

- Middle East & Africa

- - GCC Countries

- - Turkey

- - Egypt

- - South Africa

The study objectives of this report are:

- To study and analyze the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

- To understand the structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by identifying its various subsegments.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

- Focuses on the key global PARP (Poly ADP-Ribose Polymerase) Inhibitor companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

- To project the value and sales volume of PARP (Poly ADP-Ribose Polymerase) Inhibitor submarkets, with respect to key regions.

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor are as follows:

- History Year: 2014-2018

- Base Year: 2018

- Estimated Year: 2019

- Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Insights, Forecast to 2025

Table of Contents
1 Study Coverage
1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Product
1.4.2 Lynparza
1.4.3 Diraparib
1.4.4 Rucaparib
1.4.5 Talazoparib
1.4.6 Others
1.5 Market by End User
1.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by End User
1.5.2 Hospitals
1.5.3 Pharmacial
1.5.4 Retail
1.5.5 Online
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size
2.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2014-2025
2.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2014-2025
2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Growth Rate by Regions
2.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Regions
2.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers
3.1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers
3.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers
3.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Concentration Ratio (CR5 and HHI)
3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers
3.2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2014-2019)
3.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers (2014-2019)
3.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Manufacturers
3.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base Distribution, Product Types
3.4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Type
3.4.3 Date of International Manufacturers Enter into PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Product
4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Product
4.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Breakdown Data by End User
6 North America
6.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
6.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries
6.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Product
6.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by End User
7 Europe
7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries
7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Product
7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by End User
8 Asia Pacific
8.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
8.1.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries
8.1.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Product
8.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by End User
9 Central & South America
9.1 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
9.1.1 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries
9.1.2 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries
9.1.3 Brazil
9.2 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Product
9.3 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by End User
10 Middle East and Africa
10.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
10.1.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries
10.1.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Product
10.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by End User
11 Company Profiles
11.1 Tesaro
11.1.1 Tesaro Company Details
11.1.2 Company Business Overview
11.1.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.1.5 Tesaro Recent Development
11.2 Clovis Oncology
11.2.1 Clovis Oncology Company Details
11.2.2 Company Business Overview
11.2.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.2.5 Clovis Oncology Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 Company Business Overview
11.3.AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.3.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.3.5 AstraZeneca Recent Development
11.4 Abbvie
11.4.1 Abbvie Company Details
11.4.2 Company Business Overview
11.4.3 Abbvie PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Abbvie PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.4.5 Abbvie Recent Development
12 Future Forecast
12.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Regions
12.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Regions 2019-2025
12.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Regions 2019-2025
12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Product
12.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Product 2019-2025
12.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Product 2019-2025
12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by End User
12.4 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.6 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.7 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.8 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables and Figures
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Picture
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segments
Table Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Covered
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Product 2019-2025 (K MT) & (Million US$)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product 2014-2025
Figure Lynparza Product Picture
Table Major Manufacturers of Lynparza
Figure Diraparib Product Picture
Table Major Manufacturers of Diraparib
Figure Rucaparib Product Picture
Table Major Manufacturers of Rucaparib
Figure Talazoparib Product Picture
Table Major Manufacturers of Talazoparib
Figure Others Product Picture
Table Major Manufacturers of Others
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by End User 2019-2025 (K MT)
Figure Hospitals
Figure Pharmacial
Figure Retail
Figure Online
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Report Years Considered
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size 2014-2025 (Million US$)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2014-2025 (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Regions 2014-2019 (K MT) & (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Regions 2014-2019 (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Regions 2014-2019
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Regions 2014-2019
Figure 2018 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Regions
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Regions 2014-2019 (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions 2014-2019
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions 2014-2019
Figure 2018 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2014-2019) (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Manufacturers (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2014-2019) (Million USD)
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers (2014-2019)
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Share by Manufacturers in 2018
Table Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (2014-2019) (USD/MT)
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Type
Table Date of International Manufacturers Enter into PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Product (2014-2019) (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Product (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product in 2018
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Product (2014-2019) (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Product (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Product (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Product in 2018
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Product 2014-2019 (USD/MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by End User (2014-2019) (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by End User (2014-2019)
Figure Global Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by End User (2014-2019)
Figure Global Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by End User in 2018
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K MT)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019) (K MT)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019) (Million US$)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries
Figure United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (K MT)
Figure Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Product (2014-2019) (K MT)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Product
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by End User (2014-2019) (K MT)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by End User (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by End User
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K MT)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019) (K MT)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019) (Million US$)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries
Figure Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Product (2014-2019) (K MT)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Product
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by End User (2014-2019) (K MT)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by End User (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by End User
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K MT)
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019) (K MT)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries
Figure China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Indonesia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Malaysia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Philippines PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Thailand PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Vietnam PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Singapore PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Product (2014-2019) (K MT)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Product
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by End User (2014-2019) (K MT)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by End User
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K MT)
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019) (K MT)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019) (Million US$)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries
Figure Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Product (2014-2019) (K MT)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Product
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by End User (2014-2019) (K MT)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by End User
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K MT)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Countries (2014-2019) (K MT)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Countries
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Countries
Figure GCC Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure GCC Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K MT)
Figure South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Product (2014-2019) (K MT)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Product
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by End User (2014-2019) (K MT)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by End User
Table Tesaro Company Details
Table Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Tesaro Recent Development
Table Clovis Oncology Company Details
Table Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Clovis Oncology Recent Development
Table AstraZeneca Company Details
Table AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table AstraZeneca Recent Development
Table Abbvie Company Details
Table Abbvie PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Abbvie Recent Development
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Regions 2019-2025 (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Regions 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Regions 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Product 2019-2025 (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Product 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Product 2019-2025 (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Product 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by End User 2019-2025 (K MT)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by End User 2019-2025
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K MT)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global Pharmaceutical Intermediates Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Mar-2019        Price: US 3480 Onwards        Pages: 136
    Pharmaceutical intermediates are chemical material or chemical products, which could be applied in production of active pharmaceutical ingredients. Their production needs not production certification and they can be produced in ordinary chemical factory. There are many kinds of pharmaceutical intermediates, such as cephalosporin intermediates, vitamin intermediates, quinolones intermediates, steroid intermediates, etc. Scope of the Report: This industry is affected by the e......
  • Global Mildronate Dihydrate Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Mar-2019        Price: US 3480 Onwards        Pages: 108
    Mildronate is a registered trademark of the Grindex. Its active substance is meldonium. Meldonium is a limited-market pharmaceutical, and is an ‘anti-ischemic' drug, which means it is used to treat inadequate blood-flow to the organs, especially the heart. It is primarily used to treat patients with heart conditions that affect the body's ability to deliver oxygen to the body. It helps to protect against tissue damage from angina attacks, chronic heart failure and disorders of brain circulation.......
  • Global Transdermal Drug Patches Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Mar-2019        Price: US 3480 Onwards        Pages: 123
    A transdermal drug patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Transdermal patches are presently being marketed which can be worn anywhere from as little as eight hours to as long as seven days, depending on their therapeutic indication. Scope of the Report: Transdermal drug patches production has relatively high technology barrier and is technology intensive industry. Cur......
  • Global Hypromellose Acetate Succinate Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Mar-2019        Price: US 3480 Onwards        Pages: 124
    Hypromellose acetate succinate is an enteric coating material which was first approved in Japan in 1987. As of January 2004, this product has been approved in Korea, several countries in Europe, and USA as well as in Japan. Scope of the Report: Global major production regions are USA, Europe, China and Japan. Japan is the largest production region, which produced 163.96 ton in 2017. Europe is the second largest production region with production of 52.82 ton in 2017.......
  • Global Androstenedione Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Mar-2019        Price: US 3480 Onwards        Pages: 137
    Androstenedione: 4-Androstenedione (androst-4-ene-3,17-dione) - an endogenous weak androgen and estrogen and intermediate to/prohormone of testosterone. Scope of the Report: Androstenedione is used to evaluate the function of the adrenal gland and the ovaries or the testicles as well as the production of hormones related to the development of male sex organs and physical characteristics (androgens). It is most commonly used to determine the cause of symptoms of excess andro......
  • Global PEGylated Proteins Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Mar-2019        Price: US 3480 Onwards        Pages: 122
    PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s. Scope of the Report: The threat of substitutes arises when there are similar products developed by competitors which satisfy the market needs. When consumers have access to substitute products which can satisfy t......
  • Global Tecentriq Market Insights, Forecast to 2025
    Published: 18-Mar-2019        Price: US 3900 Onwards        Pages: 117
    The global Tecentriq market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Tecentriq market based on company, product type, end user and key regions. This report studies the global market size of Tecentriq in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global Animal Antibiotics and Antimicrobials Market Insights, Forecast to 2025
    Published: 18-Mar-2019        Price: US 3900 Onwards        Pages: 112
    The global Animal Antibiotics and Antimicrobials market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Animal Antibiotics and Antimicrobials market based on company, product type, end user and key regions. This report studies the global market size of Animal Antibiotics and Antimicrobials in key regions like North America, Europe,......
  • Global Gelatin Type Hard Capsules Market Insights, Forecast to 2025
    Published: 18-Mar-2019        Price: US 3900 Onwards        Pages: 116
    The global Gelatin Type Hard Capsules market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Gelatin Type Hard Capsules market based on company, product type, end user and key regions. This report studies the global market size of Gelatin Type Hard Capsules in key regions like North America, Europe, Asia Pacific, Central & South Am......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs